A Phase 2, Randomized, Double-BLInd, Placebo- Controlled Study of UBEnimex in Patients With Pulmonary ARTerial HYpertension (WHO Group 1) (LIBERTY)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Ubenimex (Primary)
- Indications Pulmonary arterial hypertension
- Focus Proof of concept; Therapeutic Use
- Acronyms LIBERTY
- Sponsors Eiger BioPharmaceuticals
- 29 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Jan 2018.
- 09 Nov 2017 According to Eiger BioPharmaceuticals media release, dosing has been completed in this study.
- 10 Jun 2017 Biomarkers information updated